MMP14 (matrix metallopeptidase 14 (membrane-inserted))

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumors Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MMP14 (matrix metallopeptidase 14 (membrane-inserted))

Written	2010-10	Cem Kuscu, Nikki Evensen, Jian Cao
		Division of Cancer Prevention, Stony Brook University, Stony Brook, New York 11794, USA

(Note : for Links provided by Atlas : click)

Identity

Alias_names	matrix metalloproteinase 14 (membrane-inserted)
	matrix metallopeptidase 14 (membrane-inserted)
Alias_symbol (synonym)	MT1-MMP
Other alias	MMP-X1
	MTMMP1
HGNC (Hugo)	MMP14
LocusID (NCBI)	4323
Atlas_Id	41391
Location	14q11.2 [Link to chromosome band 14q11]
Location_base_pair	Starts at 22836533 and ends at 22847599 bp from pter ( according to hg19-Feb_2009) [Mapping MMP14.png]

Fusion genes
(updated 2017)

Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

ETNK2 (1q32.1) / MMP14 (14q11.2)	MMP14 (14q11.2) / H19 (11p15.5)	MMP14 (14q11.2) / MED23 (6q23.2)
MMP14 (14q11.2) / MMP14 (14q11.2)	PDXDC1 (16p13.11) / MMP14 (14q11.2)	SFTPA2 (10q22.3) / MMP14 (14q11.2)

DNA/RNA



Description	MMP14 spans 11009 bp on chromosome 14 in the region of q11.2. It consists of 10 exons.
Transcription	The human MMP-14 (MT1-MMP) transcript has been determined to be 3558 bp in length before splicing and 1749 bp after splicing. The start codon (ATG) of MMP-14 gene exists in the first exon and the stop codon (TGA) is present in the last and longest exon of the transcribed product of MMP-14. No TATA box, which controls the expression of 30% of all genes found in the human genome, is found in the proximal region in the MMP-14 promoter. In the promoter region, Egr-1 has been reported to be one of the most important transcription factors regulating the expression of MMP-14. MMP-14 expression is also regulated by other transcription factors, including AP-4, NF-kB, c-ETS1 and p53. However, some common transcription factors, such as AP-1, AP-2 and TGF-alpha, which play major roles in the regulation of other MMPs do not have binding sites within the promoter of MMP-14. Besides these common transcription factors, MMP-14 expression is also regulated by hypoxia inducible factor 2a (HIF-2alpha) under hypoxic conditions. Two HBSs (HIF binding site) have been identified in the proximal promoter region, the one around -125 bp relative to the transcription start site is shown to affect MMP-14 transcription. Some growth factors and cytokines, e.g IL1B, EGF, TNFalpha, bFGF, GM-CSF, SF/HGF, and TGF-beta have also been reported to induce the expression of MMP-14. Two functional SNPs in the MMP-14 promoter have been found in focal-segmental glomerulosclerosis (FSGS) disease. -378 T/C and -364 G/T alterations cause a reduction in the expression of MMP-14 and correlate with significant risk reduction of FSGS. Epigenetic regulation is also involved in the regulation of MMP-14 expression. Hypermethylation of the CpG100 island, which spans a region from the proximal promoter to the 1st intron of MMP-14, and trimethylation of Histone H3 lysine-27 (known as a repressive marker) are determined as epigenetic controls causing the transcriptional silencing of MMP-14.
Pseudogene	No pseudogenes have been identified.

Protein



	Schematic representation of the domain structures of MMP-14 (domains are not scaled).

Description	Matrix metalloproteinases (MMPs) compose one of the metzincins super family also known as zinc endopeptidases. Highly conserved motif of this family contains three histidines that bind zinc ion in the catalytic site of the protein and conserved methionine. Besides the secreted MMPs of the MMP family, six membrane type-MMPs have been identified so far, all with similar domain compositions. The best characterized MT-MMP is MMP-14 or MT1-MMP, which contains seven domains from N-terminus to C-terminus: a signal peptide leading MMP-14 into the secretory pathway; a propeptide domain maintaining MMP in a latent form; a catalytic domain responsible for enzymatic activity; a hinge region maintaining proper conformation; a hemopexin domain required for substrate reorganization; a transmembrane domain anchoring MMP into the plasma membrane; and a cytoplasmic domain required for endocytosis. MT-1, MT2-, MT3- and MT5-MMPs all contain seven similar domains, whereas MT4- and MT6-MMPs lack the transmembrane and cytoplasmic domains. Both MT4- and MT6-MMPs are linked to the cell surface through GPI-anchorage. There is a furin consensus sequence (Arg¹⁰⁸-Arg¹⁰⁹-Lys¹¹⁰-Arg¹¹¹) between MMP-14 propeptide and catalytic domains. Furin has been reported to be responsible for MMP-14 activation. However, the activation mechanism of MMP-14 is still under debate. The hemopexin-like domain of MMP-14 is the largest domain, and it provides a suitable flat surface for the protein-protein interactions with the existence of four bladed beta-propeller structures.
Expression	MMP-14 is widely expressed in human tissues. Its expression has been proven in the adult human intestine, kidney, lung, ovary, placenta, prostate, and spleen. Increase in its expression level has also been observed in the wound healing area. A Mouse embryogenesis study provides evidence for the expression of MMP-14 mainly in the muscle cells, fibroblast, chondrocytes, and neural cells. MMP-14 is upregulated in most human cancers. Both cancer and stromal cells have been reported to be upregulated in tumor tissues.
Localisation	Plasma Membrane (single-pass type I membrane protein). MMP-14 contains a 24 amino acid hydrophobic motif at the C-terminus which is responsible for plasma membrane localization of MMP-14.
Function	MMP-14 plays an important role in remodelling of extracellular matrix (ECM) and enhancing cell migration. Besides the role of MMP-14 in these pathophysiological processes, it also plays an important physiological role during development. Studies performed with MMP-14 null mice have shown the importance of its function during embryogenesis as the lack of MMP-14 caused craniofacial dysmorphism, arthritis, osteopenia, dwarfism, fibrosis of soft tissues and premature death. In the adult life, MMP-14 is also required for the wound healing process. All of these functions are related to MMP-14's cleavage or activation of the protein within its substrate profile, which includes proteins in ECM, pro-MMPs, cell-adhesion molecules, cytokines, growth factors and receptors on the cell membrane. Recent studies have also demonstrated the activation of signal transduction pathways via the cytoplasmic tail of MMP-14 important for the invasion process. Functions of MMP-14 can be summarized under the categories of activation of proMMMPs; degradation of ECM; shedding of cell surface molecules; cleavage of cytokines and growth factors; and activation of ERK cascade. I-) Activation of proMMPs and degradation of ECM Pro-MMP2 was the first identified substrate of MMP-14 and the trimolecular complex consisting of MMP-14 and proMMP2-TIMP2 has been investigated very well for many years. TIMP2 (tissue inhibitor of metalloproteinases-2) is actually the inhibitor of the MMPs. However, low concentrations of TIMP-2 aids in the activation of proMMP-2 by MMP-14 within this complex by binding to the catalytic domain of MMP-14 and the C-terminal domain of pro-MMP2. Following the formation of the triplex, a second MMP-14, which is free of TIMP-2, forms a dimer with the pre-existing MMP-14 on the cell membrane and cleaves the latent pro-MMP2 to produce active MMP2. Active MMP-2 can then participate in other events such as the degradation of collagen type-IV, a major protein component of the basement membrane, which is not cleaved by MMP-14 itself. Another substrate of MMP-14 within the MMP family is the pro-MMP-13, which also functions as a collagenase in the surrounding tissue after its activation. Besides activation of MMPs, especially pro-MMP-2, MMP-14 cleaves many proteins in the ECM and changes the composition of the matrix. Type I-Type II-Type III collagen, gelatin, fibronectin, laminin-1 and -5, fibrin and proteoglycans are the major direct targets of MMP-14 in the extracellular environment. Out of these substrates, collagen makes up a significant portion of the ECM and acts as a barrier for migratory cells. Within the collagenases, which includes MMP-1, MMP-2, MMP-8, MMP-13, only MMP-14 can stimulate invasion into collagen by epithelial cells, fibroblasts, and cancer cells. MMP-14 concentrates in the protrusions of the cells, called lamellipodia in normal cells and invadopodia in cancer cells, to induce a significant increase in cell migration and invasion by degrading components of the ECM and making a path in through the surrounding tissue. In this aspect, MMP-14 should be bound to the plasma membrane in vivo, as membrane-bound MMP-14 has been demonstrated to be more proteolytically active than the soluble recombinant MMP-14. II-) Shedding of cell surface molecules Studies underlying the mechanism of the constitutive shedding of CD44 from the human melanoma cell surface implicated the necessity of MMP-14 with the presence of ADAM-10 for this process. Especially in the hyaluronan based matrix, cleavage of CD44 at the stem region by MMP-14 sheds these molecules from the cell surface and concurrently promotes the migration of the cells from the leading edge. Another cell adhesion molecule, E-cadherin, is also cleaved by MMP-14 to disrupt contact between cells. In the ischemia-induced ARF (acute renal failure), MMP-14 expression is required for the disruption of the cadherin/catenin complex. Syndecan-1 is another cell surface molecule which is cleaved by MMP-14. III-) Cleavage of cytokines and growth factors MMP-14 indirectly plays a major role in cleavage of the cytokines and growth factors by activating pro-MMP-2 and pro-MMP13. It also makes direct contact with several chemokines and growth factors including; the neutrophil chemokine IL-8, secretory leukocyte protease inhibitor, pro-tumor necrosis factor, death receptor-6, and connective tissue growth factor. IV-) Activation of ERK cascade by the cytoplasmic tail of MMP-14 In several studies, overexpression of MMP-14 has been reported to activate the ERK cascade. It is not yet clear how MMP-14 activates ERK signalling, but overexpression of the cytoplasmic-deleted form of MMP-14 has been shown to eradicate ERK activation. Within the cytoplasmic tail, the 573YCQR576 motif has been suggested to be involved in ERK activation. In addition to ERK activation, the role of MMP-14 in the p38 and JNK pathway has also been investigated. V-) Inhibition of MMP-14 function Function of MMP-14 can be abolished either by TIMPs (Tissue Inhibitor of MetalloProteinases) or proteolytic degradation. TIMP-2, -3 and -4 but not TIMP-1 specifically inactivates the functions of MMP-14. Besides TIMPs, RECK and N-Tes can also block the activity of MMP-14 in a similar manner. For the proteolytic cleavage of MMP-14, membrane bound MMP-14 should be internalized by the clathrin-dependent and caveolae-dependent pathways. There is an AP-2 binding site in the cytoplasmic domain of MMP-14, ⁵⁷¹LLY⁵⁷³ which is required for the incorporation of MMP-14 into clathrin-coated vesicles. The palmitoylation of the C574 right after the AP-2 binding site has also been demonstrated to be an essential modification for the internalization of MMP-14.
Homology	All MT-MMPs have shown a 40-50% identity according to their amino acid sequence. In the phylogenetic tree, MMP-14 shares the highest similarity rate with MT2-MMP (MMP-15).

Implicated in

Note

Entity	Various cancers
Note	Degradation of the ECM by MMP-14 has been linked to proliferation, invasion and metastasis of cancer cells in most cancer types. The expression level of MMP-14 has also been correlated with invasiveness in many cancer cell lines, especially for breast carcinoma. Increase in the MMP-14 expression level has also been observed in a variety of human tumors, including lung, gastric, breast, colon, liver, pancreatic, thyroid, head and neck, ovarian, prostate, bladder, cervical and brain tumors. Genetic alterations, such as gene amplification or activating mutations, have not been observed for MMP-14 in these cancer types, therefore up regulation of MMP-14 has been linked to the transcriptional changes during tumor formation. Immunohistochemical and in-situ hybridization analysis have demonstrated the presence of MMP-14 in both tumor cells and stromal cells. Interestingly, most of the MMP-14 expression is produced by the stromal cells rather than the cancer cells in many tumor types, including breast and lung tumors. The possible explanation for this observation is the production of Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) by the cancer cells on their cell surface. EMMPRIN stimulates the surrounding stromal cells to produce MMPs, including MMP-14. However, in some human cancers, including thyroid, brain, and head and neck cancer, a majority of the MMP-14 expression has been shown to be produced by the cancer cells rather than surrounding stromal cells. Another major role of the MMP-14 expression for tumor formation is the upregulation of VEGF production. VEGF is the key molecule for the vascularisation of tumor cells and angiogenesis. For the VEGF gene transcription, C-terminal of MMP-14 in the cytoplasmic tail has a structural region composed of ⁵⁷⁴CQRSLLDKV⁵⁸².


Entity	Atherosclerosis
Note	In the numerous stages of atherosclerosis, pro-inflammatory molecules such IL-1a, TNF-a and oxidized-LDL trigger the smooth muscle cells (SMC) and macrophages to increase their levels of MMP-14. Higher expression of MMP-14 activates its downstream molecule, pro-MMP-2, and then both MMP-14 and MMP-2 contribute to the abnormal matrix turnover, leading to the atherosclerotic plaques in the walls of arteries.


Entity	Rheumatoid disease
Note	It has been reported that fibroblasts, macrophages, and osteoclast-like cells in both the lining and sublinig layers of the rheumatoid synovial tissue have higher expression of MMP-14 and MT3-MMP. Effects of MMP-14 have been implicated in the destruction of tissue seen in arthritis. Successful suppression of the joint destruction has also been observed after treatment with one of the MMP-14 inhibitors, called FR217840.


Entity	Neurologic disease
Note	Neurons and astrocytes have been known to express MMPs and remodel the ECM after nerve injury in the body. In the case of amyotrophic lateral sclerosis, MMP-14 expression has been found to be increased in the astrocytes of affected tissues of the mouse central nervous system.


Entity	Lung disease
Note	Vascular endothelial cells and bronchial epithelial cells of the lung were injured by the high volume ventilation in the ventilator-induced lung (VIL) rat model. In the injured cells of the VIL, an increase in the MMP-14 expression has been reported. Prinomastat, an MMP-14 inhibitor, treatment of the VIL rat has also been shown to abolish the injury.


Entity	Kidney disease
Note	Data suggest that the development of crescentic glomerulonephritis, a kidney disease characterized by inflammation of the glomeruli or small blood vessels, triggered by the expression of MMP-14 in macrophages. In this disease, MMP-14 activates proMMP-2, and then they both contribute to the pathological degradation of the ECM.

Bibliography

MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts.

Afzal S, Lalani EN, Poulsom R, Stubbs A, Rowlinson G, Sato H, Seiki M, Stamp GW.

Hum Pathol. 1998 Feb;29(2):155-65.

PMID 9490275

ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.

Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, Voelcker V, Sleeman JP, Simon JC.

J Invest Dermatol. 2009 Jun;129(6):1471-82. Epub 2008 Oct 30.

PMID 18971959

Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer.

Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S.

J Biol Chem. 2008 Mar 7;283(10):6232-40. Epub 2008 Jan 3.

PMID 18174174

Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration.

Cao J, Kozarekar P, Pavlaki M, Chiarelli C, Bahou WF, Zucker S.

J Biol Chem. 2004 Apr 2;279(14):14129-39. Epub 2004 Jan 16.

PMID 14729674

Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase.

Cao J, Rehemtulla A, Pavlaki M, Kozarekar P, Chiarelli C.

J Biol Chem. 2005 Mar 25;280(12):10974-80. Epub 2005 Jan 6.

PMID 15637056

Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells.

Chernov AV, Sounni NE, Remacle AG, Strongin AY.

J Biol Chem. 2009 May 8;284(19):12727-34. Epub 2009 Mar 13.

PMID 19286653

Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14).

Covington MD, Burghardt RC, Parrish AR.

Am J Physiol Renal Physiol. 2006 Jan;290(1):F43-51. Epub 2005 Aug 2.

PMID 16077081

Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340).

Foda HD, Rollo EE, Drews M, Conner C, Appelt K, Shalinsky DR, Zucker S.

Am J Respir Cell Mol Biol. 2001 Dec;25(6):717-24.

PMID 11726397

Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration.

Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, Foidart JM.

J Cell Sci. 2001 Aug;114(Pt 16):2967-76.

PMID 11686300

Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP).

Gingras D, Bousquet-Gagnon N, Langlois S, Lachambre MP, Annabi B, Beliveau R.

FEBS Lett. 2001 Oct 26;507(2):231-6.

PMID 11684104

Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium.

Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA.

J Biol Chem. 1999 Aug 6;274(32):22679-85.

PMID 10428849

Macrophage-derived MT1-MMP and increased MMP-2 activity are associated with glomerular damage in crescentic glomerulonephritis.

Hayashi K, Horikoshi S, Osada S, Shofuda K, Shirato I, Tomino Y.

J Pathol. 2000 Jul;191(3):299-305.

PMID 10878552

MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H.

Cell. 1999 Oct 1;99(1):81-92.

PMID 10520996

Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase.

Itoh Y, Kajita M, Kinoh H, Mori H, Okada A, Seiki M.

J Biol Chem. 1999 Nov 26;274(48):34260-6.

PMID 10567400

Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis.

Jiang A, Lehti K, Wang X, Weiss SJ, Keski-Oja J, Pei D.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13693-8. Epub 2001 Nov 6.

PMID 11698655

Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme.

Knauper V, Will H, Lopez-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G.

J Biol Chem. 1996 Jul 19;271(29):17124-31.

PMID 8663255

Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP.

Kojima S, Itoh Y, Matsumoto S, Masuho Y, Seiki M.

FEBS Lett. 2000 Sep 1;480(2-3):142-6.

PMID 11034316

The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.

Lee MH, Atkinson S, Rapti M, Handsley M, Curry V, Edwards D, Murphy G.

Cancer Lett. 2010 Apr 1;290(1):114-22. Epub 2009 Oct 7.

PMID 19815335

Characterization of the transcriptional regulation of the human MT1-MMP gene and association of risk reduction for focal-segmental glomerulosclerosis with two functional promoter SNPs.

Munkert A, Helmchen U, Kemper MJ, Bubenheim M, Stahl RA, Harendza S.

Nephrol Dial Transplant. 2009 Mar;24(3):735-42. Epub 2008 Oct 16.

PMID 18927121

Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer.

Overall CM, Dean RA.

Cancer Metastasis Rev. 2006 Mar;25(1):69-75. (REVIEW)

PMID 16680573

Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis.

Pap T, Shigeyama Y, Kuchen S, Fernihough JK, Simmen B, Gay RE, Billingham M, Gay S.

Arthritis Rheum. 2000 Jun;43(6):1226-32.

PMID 10857781

Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP.

Pei D.

J Biol Chem. 1999 Mar 26;274(13):8925-32.

PMID 10085137

Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.

Petrella BL, Lohi J, Brinckerhoff CE.

Oncogene. 2005 Feb 3;24(6):1043-52.

PMID 15592504

Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia.

Poincloux R, Lizarraga F, Chavrier P.

J Cell Sci. 2009 Sep 1;122(Pt 17):3015-24. (REVIEW)

PMID 19692588

Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase.

Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, Shah PK, Libby P.

J Biol Chem. 1999 Apr 23;274(17):11924-9.

PMID 10207013

Elevated expression of membrane type 1 metalloproteinase (MT1-MMP) in reactive astrocytes following neurodegeneration in mouse central nervous system.

Rathke-Hartlieb S, Budde P, Ewert S, Schlomann U, Staege MS, Jockusch H, Bartsch JW, Frey J.

FEBS Lett. 2000 Sep 22;481(3):227-34.

PMID 11007969

Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding.

Stamenkovic I, Yu Q.

J Invest Dermatol. 2009 Jun;129(6):1321-4.

PMID 19434087

Structural features of a superfamily of zinc-endopeptidases: the metzincins.

Stocker W, Bode W.

Curr Opin Struct Biol. 1995 Jun;5(3):383-90. (REVIEW)

PMID 7583637

Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease.

Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI.

J Biol Chem. 1995 Mar 10;270(10):5331-8.

PMID 7890645

Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates.

Tam EM, Morrison CJ, Wu YI, Stack MS, Overall CM.

Proc Natl Acad Sci U S A. 2004 May 4;101(18):6917-22. Epub 2004 Apr 26.

PMID 15118097

Granulocyte-macrophage colony-stimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells.

Tomita T, Fujii M, Tokumaru Y, Imanishi Y, Kanke M, Yamashita T, Ishiguro R, Kanzaki J, Kameyama K, Otani Y.

Cancer Lett. 2000 Aug 1;156(1):83-91.

PMID 10840163

Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.

Velasco G, Cal S, Merlos-Suarez A, Ferrando AA, Alvarez S, Nakano A, Arribas J, Lopez-Otin C.

Cancer Res. 2000 Feb 15;60(4):877-82.

PMID 10706098

cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment.

Will H, Hinzmann B.

Eur J Biochem. 1995 Aug 1;231(3):602-8.

PMID 7649159

Transcription factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloproteinase expression in endothelium.

Yun S, Dardik A, Haga M, Yamashita A, Yamaguchi S, Koh Y, Madri JA, Sumpio BE.

J Biol Chem. 2002 Sep 20;277(38):34808-14. Epub 2002 Jul 1.

PMID 12093818

Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.

Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K.

Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7.

PMID 10737763

Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.

Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J.

Int J Cancer. 1998 Mar 2;75(5):780-6.

PMID 9495249

Citation

This paper should be referenced as such :

Kuscu, C ; Evensen, N ; Cao, J

MMP14 (matrix metallopeptidase 14 (membrane-inserted))

Atlas Genet Cytogenet Oncol Haematol. 2011;15(6):502-506.

Free journal version : [ pdf ] [ DOI ]

On line version : http://AtlasGeneticsOncology.org/Genes/MMP14ID41391ch14q11.html

Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 2 ]

Lung: Translocations in Adenocarcinoma
t(14;16)(q11;p13) PDXDC1/MMP14

External links

	Nomenclature
HGNC (Hugo)	MMP14 7160
	Cards
Atlas	MMP14ID41391ch14q11
Entrez_Gene (NCBI)	MMP14 4323 matrix metallopeptidase 14
Aliases	MMP-14; MMP-X1; MT-MMP; MT-MMP;
	MT1-MMP; MT1MMP; MTMMP1; WNCHRS
GeneCards (Weizmann)	MMP14
Ensembl hg19 (Hinxton)	ENSG00000157227 [Gene_View]
Ensembl hg38 (Hinxton)	ENSG00000157227 [Gene_View] ENSG00000157227 [Sequence] chr14:22836533-22847599 [Contig_View] MMP14 [Vega]
ICGC DataPortal	ENSG00000157227
TCGA cBioPortal	MMP14
AceView (NCBI)	MMP14
Genatlas (Paris)	MMP14
WikiGenes	4323
SOURCE (Princeton)	MMP14
Genetics Home Reference (NIH)	MMP14
	Genomic and cartography
GoldenPath hg38 (UCSC)	MMP14 - chr14:22836533-22847599 + 14q11.2 [Description] (hg38-Dec_2013)
GoldenPath hg19 (UCSC)	MMP14 - 14q11.2 [Description] (hg19-Feb_2009)
Ensembl	MMP14 - 14q11.2 [CytoView hg19] MMP14 - 14q11.2 [CytoView hg38]
Mapping of homologs : NCBI	MMP14 [Mapview hg19] MMP14 [Mapview hg38]
OMIM	277950 600754
	Gene and transcription
Genbank (Entrez)	AK291325 AK312657 BC039581 BC064803 BQ009340
RefSeq transcript (Entrez)	NM_004995
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)	MMP14
Cluster EST : Unigene	Hs.2399 [ NCBI ]
CGAP (NCI)	Hs.2399
Alternative Splicing Gallery	ENSG00000157227
Gene Expression	MMP14 [ NCBI-GEO ] MMP14 [ EBI - ARRAY_EXPRESS ] MMP14 [ SEEK ] MMP14 [ MEM ]
Gene Expression Viewer (FireBrowse)	MMP14 [ Firebrowse - Broad ]
SOURCE (Princeton)	Expression in : [Datasets] [Normal Tissue Atlas] [carcinoma Classsification] [NCI60]
Genevestigator	Expression in : [tissues] [cell-lines] [cancer] [perturbations]
BioGPS (Tissue expression)	4323
GTEX Portal (Tissue expression)	MMP14
Human Protein Atlas	ENSG00000157227-MMP14 [pathology] [cell] [tissue]
	Protein : pattern, domain, 3D structure
UniProt/SwissProt	P50281 [function] [subcellular_location] [family_and_domains] [pathology_and_biotech] [ptm_processing] [expression] [interaction]
NextProt	P50281 [Sequence] [Exons] [Medical] [Publications]
With graphics : InterPro	P50281
Splice isoforms : SwissVar	P50281
Catalytic activity : Enzyme	3.4.24.80 [ Enzyme-Expasy ] 3.4.24.80 3.4.24.80 [ IntEnz-EBI ] 3.4.24.80 [ BRENDA ] 3.4.24.80 [ KEGG ]
PhosPhoSitePlus	P50281
Domaine pattern : Prosite (Expaxy)	CYSTEINE_SWITCH (PS00546) HEMOPEXIN (PS00024) HEMOPEXIN_2 (PS51642) ZINC_PROTEASE (PS00142)
Domains : Interpro (EBI)	Hemopexin-like_dom Hemopexin-like_dom_sf Hemopexin-like_repeat Hemopexin_CS M10A_MMP MetalloPept_cat_dom_sf MMP14 Pept_M10_metallopeptidase Pept_M10A Pept_M10A_metallopeptidase_C Pept_M10A_Zn_BS Peptidase_Metallo Peptidoglycan-bd-like PGBD-like_sf PGBDSf
Domain families : Pfam (Sanger)	DUF3377 (PF11857) Hemopexin (PF00045) Peptidase_M10 (PF00413) PG_binding_1 (PF01471)
Domain families : Pfam (NCBI)	pfam11857 pfam00045 pfam00413 pfam01471
Domain families : Smart (EMBL)	HX (SM00120) ZnMc (SM00235)
Conserved Domain (NCBI)	MMP14
DMDM Disease mutations	4323
Blocks (Seattle)	MMP14
PDB (RSDB)	1BQQ 1BUV 2MQS 3C7X 3MA2 3X23 4P3C 4P3D 4QXU 5H0U
PDB Europe	1BQQ 1BUV 2MQS 3C7X 3MA2 3X23 4P3C 4P3D 4QXU 5H0U
PDB (PDBSum)	1BQQ 1BUV 2MQS 3C7X 3MA2 3X23 4P3C 4P3D 4QXU 5H0U
PDB (IMB)	1BQQ 1BUV 2MQS 3C7X 3MA2 3X23 4P3C 4P3D 4QXU 5H0U
Structural Biology KnowledgeBase	1BQQ 1BUV 2MQS 3C7X 3MA2 3X23 4P3C 4P3D 4QXU 5H0U
SCOP (Structural Classification of Proteins)	1BQQ 1BUV 2MQS 3C7X 3MA2 3X23 4P3C 4P3D 4QXU 5H0U
CATH (Classification of proteins structures)	1BQQ 1BUV 2MQS 3C7X 3MA2 3X23 4P3C 4P3D 4QXU 5H0U
Superfamily	P50281
Human Protein Atlas [tissue]	ENSG00000157227-MMP14 [tissue]
Peptide Atlas	P50281
HPRD	02856
IPI	IPI00218398 IPI01022293 IPI01022788
	Protein Interaction databases
DIP (DOE-UCLA)	P50281
IntAct (EBI)	P50281
FunCoup	ENSG00000157227
BioGRID	MMP14
STRING (EMBL)	MMP14
ZODIAC	MMP14
	Ontologies - Pathways
QuickGO	P50281
Ontology : AmiGO	skeletal system development angiogenesis ovarian follicle development response to hypoxia endothelial cell proliferation endochondral ossification endopeptidase activity metalloendopeptidase activity metalloendopeptidase activity metalloendopeptidase activity serine-type endopeptidase activity integrin binding protein binding extracellular space extracellular space nucleus cytoplasm Golgi lumen cytosol plasma membrane plasma membrane integral component of plasma membrane focal adhesion proteolysis proteolysis response to oxidative stress zinc ion binding male gonad development response to mechanical stimulus response to hormone positive regulation of myotube differentiation positive regulation of protein processing response to organic cyclic compound protein processing extracellular matrix disassembly extracellular matrix organization positive regulation of cell growth lung development positive regulation of cell migration collagen catabolic process collagen catabolic process extracellular matrix cytoplasmic vesicle zymogen activation zymogen activation endodermal cell differentiation chondrocyte proliferation melanosome astrocyte cell migration response to estrogen macropinosome intermediate filament cytoskeleton positive regulation of B cell differentiation negative regulation of Notch signaling pathway embryonic cranial skeleton morphogenesis branching morphogenesis of an epithelial tube tissue remodeling cell motility negative regulation of focal adhesion assembly head development metalloaminopeptidase activity metalloaminopeptidase activity craniofacial suture morphogenesis regulation of protein localization to plasma membrane positive regulation of macrophage migration response to odorant
Ontology : EGO-EBI	skeletal system development angiogenesis ovarian follicle development response to hypoxia endothelial cell proliferation endochondral ossification endopeptidase activity metalloendopeptidase activity metalloendopeptidase activity metalloendopeptidase activity serine-type endopeptidase activity integrin binding protein binding extracellular space extracellular space nucleus cytoplasm Golgi lumen cytosol plasma membrane plasma membrane integral component of plasma membrane focal adhesion proteolysis proteolysis response to oxidative stress zinc ion binding male gonad development response to mechanical stimulus response to hormone positive regulation of myotube differentiation positive regulation of protein processing response to organic cyclic compound protein processing extracellular matrix disassembly extracellular matrix organization positive regulation of cell growth lung development positive regulation of cell migration collagen catabolic process collagen catabolic process extracellular matrix cytoplasmic vesicle zymogen activation zymogen activation endodermal cell differentiation chondrocyte proliferation melanosome astrocyte cell migration response to estrogen macropinosome intermediate filament cytoskeleton positive regulation of B cell differentiation negative regulation of Notch signaling pathway embryonic cranial skeleton morphogenesis branching morphogenesis of an epithelial tube tissue remodeling cell motility negative regulation of focal adhesion assembly head development metalloaminopeptidase activity metalloaminopeptidase activity craniofacial suture morphogenesis regulation of protein localization to plasma membrane positive regulation of macrophage migration response to odorant
Pathways : KEGG	TNF signaling pathway GnRH signaling pathway
REACTOME	P50281 [protein]
REACTOME Pathways	R-HSA-1592389 [pathway]
NDEx Network	MMP14
Atlas of Cancer Signalling Network	MMP14
Wikipedia pathways	MMP14
	Orthology - Evolution
OrthoDB	4323
GeneTree (enSembl)	ENSG00000157227
Phylogenetic Trees/Animal Genes : TreeFam	MMP14
HOGENOM	P50281
Homologs : HomoloGene	MMP14
Homology/Alignments : Family Browser (UCSC)	MMP14
	Gene fusions - Rearrangements
Fusion : Mitelman	MMP14/H19 [14q11.2/11p15.5]
Fusion : Mitelman	PDXDC1/MMP14 [16p13.11/14q11.2] [t(14;16)(q11;p13)]
Fusion Portal	PDXDC1 16p13.11 MMP14 14q11.2 PRAD
Fusion : Quiver	MMP14
	Polymorphisms : SNP and Copy number variants
NCBI Variation Viewer	MMP14 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)	MMP14
dbVar	MMP14
ClinVar	MMP14
1000_Genomes	MMP14
Exome Variant Server	MMP14
ExAC (Exome Aggregation Consortium)	ENSG00000157227
GNOMAD Browser	ENSG00000157227
Varsome Browser	MMP14
Genetic variants : HAPMAP	4323
Genomic Variants (DGV)	MMP14 [DGVbeta]
DECIPHER	MMP14 [patients] [syndromes] [variants] [genes]
CONAN: Copy Number Analysis	MMP14
	Mutations
ICGC Data Portal	MMP14
TCGA Data Portal	MMP14
Broad Tumor Portal	MMP14
OASIS Portal	MMP14 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMIC	MMP14 [overview] [genome browser] [tissue] [distribution]
Mutations and Diseases : HGMD	MMP14
LOVD (Leiden Open Variation Database)	Whole genome datasets
LOVD (Leiden Open Variation Database)	LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)	LOVD 3.0 shared installation
BioMuta	search MMP14
DgiDB (Drug Gene Interaction Database)	MMP14
DoCM (Curated mutations)	MMP14 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)	MMP14 (select a term)
intoGen	MMP14
NCG5 (London)	MMP14
Cancer3D	MMP14(select the gene name)
Impact of mutations	[PolyPhen2] [Provean] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
	Diseases
OMIM	277950 600754
Orphanet	3042 11654
DisGeNET	MMP14
Medgen	MMP14
Genetic Testing Registry	MMP14
NextProt	P50281 [Medical]
TSGene	4323
GENETests	MMP14
Target Validation	MMP14
Huge Navigator	MMP14 [HugePedia]
snp3D : Map Gene to Disease	4323
BioCentury BCIQ	MMP14
ClinGen	MMP14
	Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD	4323
Chemical/Pharm GKB Gene	PA30872
Clinical trial	MMP14
	Miscellaneous
canSAR (ICR)	MMP14 (select the gene name)
DataMed Index	MMP14
	Probes
	Litterature
PubMed	493 Pubmed reference(s) in Entrez
GeneRIFs	Gene References Into Functions (Entrez)
CoreMine	MMP14
EVEX	MMP14
GoPubMed	MMP14
iHOP	MMP14

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed

Search in all EBI NCBI

indexed on : Thu Jan 17 19:01:30 CET 2019

Home Genes Leukemias Solid Tumors Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.